Beiersdorf
This article was originally published in The Rose Sheet
Executive Summary
Company's 85 employees from wound care factory in Hamburg/Hausbruch "will be offered a comparable job in the production of skin care products in Hamburg/Eimsbüttel" under previously announced supply chain reorganization, firm says. Initiative, which was unveiled in November, is intended to optimize firm's international supply chain, including purchasing, production, distribution and delivery, and help Beiersdorf "introduce innovations better, faster and more efficiently to further strengthen the company's position in an increasingly competitive market," according to the firm (1"The Rose Sheet" Nov. 28, 2005, In Brief). Reorganization is expected to generate annual cost savings of €100 mil...
You may also be interested in...
Beiersdorf
Company unveils supply chain realignment plan Nov. 22. Three-year initiative aims to "optimize" firm's international supply chain, including purchasing, production, distribution and delivery, and help Beiersdorf "introduce innovations better, faster and more efficiently to further strengthen the company's position in an increasingly competitive market," according to the company. Beiersdorf will "create a seamless, global supply chain network, in which all production and logistics processes are managed centrally." Firm additionally will seek to "make its production and logistics network more efficient and adjust capacities in Europe" by reducing production, warehouse locations and headcount in the region. Company anticipates resulting cost savings of about €100 mil. per year. From 2006 to 2008, however, the firm said it expects to record one-time charges of about €220 mil...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.